Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Genflow Biosciences Plc ( (GB:GENF) ).
Genflow Biosciences reported a year of scientific and clinical progress in 2025, highlighting completion of dosing in its blinded SIRT6-based gene therapy trial in aging dogs without observed adverse events, with initial efficacy data expected in the first quarter of 2026 and longer-term results by mid-year. The company advanced its MASH program by repositioning GF-1002 toward patients with advanced fibrosis, generating new preclinical proof-of-concept data on hepatocellular carcinoma prevention, and exploring mRNA/LNP delivery to enable repeat dosing and reduce costs, while also entering ophthalmology with a glaucoma program aimed at neuroprotection of retinal ganglion cells in a market forecast to reach up to $14 billion in the early 2030s. Additional efforts included steady progress in a sarcopenia program and the ExoFastTrack initiative, both supporting the broader pipeline. Looking to 2026, Genflow plans to rationalize its portfolio around the most promising, partner-attractive assets and pursue early-stage licensing and collaboration deals to secure non-dilutive funding, strengthen its partner ecosystem, and support its transition into a more mature, growth-oriented phase with multiple upcoming data readouts and a growing intellectual property base.
The most recent analyst rating on (GB:GENF) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Genflow Biosciences Plc stock, see the GB:GENF Stock Forecast page.
Spark’s Take on GB:GENF Stock
According to Spark, TipRanks’ AI Analyst, GB:GENF is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, continued cash burn) and a weakened balance sheet with negative equity. Technicals are moderately supportive given the price trend above key moving averages, but valuation remains pressured due to losses and no dividend support.
To see Spark’s full report on GB:GENF stock, click here.
More about Genflow Biosciences Plc
Genflow Biosciences Plc is a UK-headquartered biotechnology company with R&D operations in Belgium, focused on pioneering gene therapies to decelerate the aging process and extend healthy lifespan. Its lead candidate, GF-1002, delivers a centenarian variant of the SIRT6 gene and is being developed across multiple indications, including a 12‑month proof‑of‑concept trial in aged dogs and a planned clinical program in metabolic dysfunction-associated steatohepatitis (MASH), targeting a fast-growing aging population and unmet chronic disease markets.
Average Trading Volume: 3,988,083
Technical Sentiment Signal: Buy
Current Market Cap: £9.01M
For an in-depth examination of GENF stock, go to TipRanks’ Overview page.